Invasive fungal infections in the paediatric and neonatal population: diagnostics and management issues.
Invasive fungal infections in children appear to have increased over the past few decades. Especially neonates and children with primary and secondary immunodeficiencies are at risk. Candida and Aspergillus spp. are the most commonly isolated organisms. In addition, Malassezia may cause systemic infections in newborns and zygomycosis is important because of its rising incidence and high case fatality rate. Timely diagnosis and initiation of appropriate antifungal therapy is imperative for improving outcomes. However, traditional techniques are time-consuming and representative sample material, using invasive procedures, may be difficult to obtain in the paediatric setting. This review provides an overview of the advances in detection and rapid species identification, with a focus on issues relevant in these settings. Subsequently, the current antifungal treatment options for neonates and children are discussed in light of the antifungal spectrum of the available agents and the specific pharmacokinetic properties in different age groups. Although a multitude of newer antifungal compounds have become available within the last decade, further studies are necessary to clearly establish the role for each of these agents among neonates and children.
Arendrup
M C
MC
Unit of Mycology and Parasitology, Statens Serum Institut, Copenhagen, Denmark.
Fisher
B T
BT
Zaoutis
T E
TE
D020095:Absidia / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D000935:Antifungal Agents / Q000627:therapeutic use; D001230:Aspergillus / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D002175:Candida / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008290:Malassezia / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D009089:Mucor / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification; D009181:Mycoses / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology
D000935:Antifungal Agents